XOMA-BIOTEC - 500 Beiträge pro Seite

[fromToronto]

.
no comment

[Micky_Maus]

Die Bewertung von XOMA ist immer noch viel zu hoch, man betrachte nur mal die Fundamentals--->http://biz.yahoo.com/p/x/xoma.html

Das9fache vom Umsatz wird bezahlt, kaum noch Geld in der Kasse, knapp 60 Mio $ Schulden.

Einzig Genentech kann Xoma noch retten. Würde Xoma derzeit nicht anfassen.

[fromToronto]

Der XOMA "SPEZIALIST" M_M hat gesprochen!

Ja genau mach sie runter dann kann man für 2 EUro einsteigen!?

[Julia@]

Hallo zusammen,

kam gestern durch Zufall in diesen Thread
und beobachte so einige Sprücheklopfer.
Micky Maus pusht erst diesen Wert (weil investiert),

....#74 von Micky_Maus 24.05.02 15:41:46 Beitrag Nr.: 6.480.162 6480162
Dieses Posting: versenden | melden | drucken | Antwort schreiben
Schon wieder +10% !!
Die Rally ist noch net zuende. XOMA profitiert von Biogen
....
dann hat er wohl verkauft, darum wird jetzt versucht mit irgendwelchen Behauptungen Panik zu verbreiten
um billigst reinzukommen!?
Bewirken wird er nichts, Kurse werden in USA gemacht.

[fromToronto]

XOMAS UND GENENTECH

Für Leute die English verstehen eine SUPERNACHRICHT.

Serono and Genentech Expand Raptiva Agreement to Additional EmergingMarkets in Asia

GENEVA, Feb 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- Serono S.A. (virt-x: SEO and NYSE: SRA) Serono announced today that Genentech Inc. (NYSE: DNA) has extended Serono`s exclusive license to develop and market Raptiva(TM) (efalizumab) to include an additional 15 Asian countries. This expands the scope of the Genentech-Serono collaboration for Raptiva(TM), which was first established in August 2002.

"The extension of our territory under this important license agreement highlights Serono`s considerable presence in Asia and will enable us to bring an innovative new therapy to patients with psoriasis in a region with great growth potential," said Ernesto Bertarelli, Chief Executive Officer of Serono. The 15 countries included in the extended agreement are China, S. Korea, Taiwan, Hong Kong, Singapore, Malaysia, Thailand, the Philippines, Indonesia, Vietnam, Cambodia, Laos, Nepal, Myanmar and Brunei.

As a result of the new agreement, Serono will now develop and market Raptiva(TM) worldwide outside of the United States and Japan. Development and marketing rights in the United States remain with Genentech and its U.S. partner XOMA (Nasdaq: XOMA). Genentech retains exclusive marketing rights in Japan.

Serono plans to file for approval of Raptiva(TM) for moderate to severe psoriasis in Europe in the first quarter of this year and in most of the countries included in this new agreement in the first half of 2004. Genentech and XOMA announced submission of a Biologics License application for Raptiva(TM) to the U.S. Food and Drug Administration on December 23, 2002. Financial terms of the agreement were not disclosed. Raptiva(TM) is a recombinant humanized monoclonal antibody under evaluation for the treatment of moderate-to-severe plaque psoriasis and is in phase 2 trials for rheumatoid arthritis.

About Serono

Serono is a global biotechnology leader. The Company has six recombinant products on the market, Gonal-F(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Rebif(R), Serostim(R) and Saizen(R) (Luveris(R) is not approved in the USA). In addition to being the world leader in reproductive health, Serono has strong market positions in neurology, metabolism and growth. The Company`s research programs are focused on growing these businesses and on establishing new therapeutic areas. Currently, there are over 30 projects in development.

In 2002, Serono achieved worldwide revenues of US$1.546 billion, and a net income of US$321 million, making it the third largest biotech company in the world. The Company operates in 45 countries, and its products are sold in over 100 countries. Bearer shares of Serono S.A., the holding company, are traded on the virt-x (SEO) and its American Depositary Shares are traded on the New York Stock Exchange (SRA).

About Raptiva(TM)

Raptiva(TM) is designed to inhibit the adhesion of T-lymphocytes to other cell types by inhibiting the binding of LFA-1 to ICAM-1. This mechanism of action has a number of effects depending upon the cell type, which include: (1) inhibition of T-lymphocyte interactions with tissue-specific cells, (2) inhibition of T-lymphocyte migration, (3) inhibition of T-lymphocyte activation, proliferation and cytokine release. In the Phase III studies, Raptiva(TM) was given as a once-a-week subcutaneous injection.

Some of the statements in this press release are forward looking. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Serono S.A. and affiliates to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements are based on Serono`s current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono`s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on May 21 2002. These factors include any failure or delay in Serono`s ability to develop new products, any failure to receive anticipated regulatory approvals, any problems in commercializing current products as a result of competition or other factors, our ability to obtain reimbursement coverage for our products, and government regulations limiting our ability to sell our products. Serono has no responsibility to update the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.



For more information, please contact:
Serono in Geneva, Switzerland:
Media Relations: Investor Relations:
Tel: [phone] Tel: [phone]
Fax: [phone] Fax: [phone]
www.serono.com Reuters: SEOZ.VX / SRA.N
Bloomberg: SEO VX / SRA US

.

[fromToronto]

.

.

.

[Micky_Maus]

Oh @Julia, da hast du leider daneben gegriffen. Wer meinem Kommentar vom 24.5.02 folgte, hatte noch eine schöne Zeit vor sich, sieh mal den Chart:



Wie schon gesagt: die Gewinne waren fett und es hat Spaß gemacht.

Zum Aussteigen wird aber nicht geklingelt, Gelegenheit war reichlich. Jetzt ist das Kind in den Brunnen gefallen. Man sollte sich nie in eine Aktie verlieben.

Bin jetzt dick in Caliper (Nasday: CALP) investiert, da sehen die Zahlen besser aus. Guck mal, was die an Cash haben--->http://biz.yahoo.com/p/c/calp.html

XOMA ade. Vielleicht bei 2$ wieder ein paar Stücke.

[Sylow]

Wer abgewartet hat, konnte auch wieder bessere Zeiten der Aktie erleben (siehe chart).
Es sieht ganz gut aus: Steigender Kurs bei steigenden Umsätzen. Vielleicht gibt es bald "news"??
Wieso funktioniert den das mit dem Bild hier nicht??
Schaut selbst nach:
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?s…

[fromToronto]

.




....habe am Freitag XOMA an der Nasdaq

verkauft bei Höchststand hab ich 8,51 bekommen.

....das sieht mir doch sehr nach >Kurstreiberei aus!

>Komisch. dass wenn Negatives ansteht die Kurse immer hochlaufen!


.